 acelRx Pharmaceuticals, Inc. (NASDAQ:ACRX ) reported fourth quarter 2019 net sales of $3.6 million which is 49% higher than the third quarter with solid growth expected for the rest of this year. 
 we also announced our previously previewed fourth quarter 2019 financial results and provided an update on our commercial launch of dSUVIA in a press release. 
 we also announced the signing of a definitive agreement to acquire Tetraphase Pharmaceuticals, as well as entering into a co-promotion agreement which allows us to more quickly realize some key benefits from the transaction. 
 we expect significant revenue and cost synergies from the combination of the two companies. 
 in addition, we will continue to responsibly manage our cash. 
 we expect our 2020 quarterly cash operating expenses to range from $9 million to $12 million excluding stock comp, depending upon the quarter or $10 million to $13 million including stock comp based compensation of $1 million annually.    
 # 1_#1 _ # 1_#1 _ =    # 1 1.25 in.125 in.25 in 